TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06173596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Participants will receive ALXN2080 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Participants will receive ALXN2080 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Participants will receive ALXN2080 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive Itraconazole orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole (AxMP)
Description: Participants will receive Fluconazole orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine (AxMP)
Description: Participants will receive Carbamazepine orally.
Study: NCT05981534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 4000IU/day vitamin D supplement will be used for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used for 6 months
Study: NCT06064825

Intervention type: OTHER
Intervention: 2 year follow-up of neurodevelopment using a parental questionnaire
Description: A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial

Intervention type: OTHER
Intervention: 2 year follow-up of neurodevelopment using a parental questionnaire
Description: A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
Study: NCT04582734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Description: Cognitive-behavioural therapy intervention
Study: NCT06266273

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05686759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Undiluted I.V.-Hepabig inj(GC5103)
Description: undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diluted I.V.-Hepabig inj(GC5103)
Description: Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
Study: NCT05646745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Transobturator Fascia Lata Sling
Description: Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip.
Study: NCT04995120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy TP regimen combined with Toripalimab
Description: Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles.
Study: NCT05248984

Intervention type: DRUG
Intervention: Ketorolac
Description: Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg

Intervention type: DRUG
Intervention: Ketorolac
Description: Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg
Study: NCT06015581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workforce Development: Tailored Motivational Interviewing and Technical Assistance
Description: TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Management, Mystery Shopper Feedback
Description: Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality Management, Mystery Shopper Feedback
Description: Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.
Study: NCT04881136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQ™
Description: The physical device is the Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data that will be used for gait analysis.
Study: NCT05125133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITENs + ITWS
Description: A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
Study: NCT04978636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous low-tidal volume ventilation with using FiO2 of 0.21
Description: The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous low tidal volume ventilation with using FiO2 of 1.0
Description: The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apnea During CPB
Description: There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
Study: NCT05968326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Autogene cevumeran will be administered intravenously (IV) at a recommended dose at specified timepoints.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered IV at a dose of 1680 milligrams (mg) at specified timepoints.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.
Study: NCT06153160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemaShock device
Description: The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
Study: NCT05201638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 tablets
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching IMU-838 tablets
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Study: NCT05861219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: water immersion
Description: mild physical activity then water immersion in tub
Study: NCT05592249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task MC
Description: Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 6 weeks in clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task MM
Description: Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 6 weeks in clinic.
Study: NCT06083415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental health measures
Description: MRI will be used to confirm the presence of breast buds, to measure the size of the ovaries and uterus, as well as the fraction of fat mass (abdominal, subcutaneous, liver and bone marrow). The bood and urine tests will allow to measure different biological and metabolic parameters. The presence of endocrine disruptors will be determined in the hair. The bone age x ray will be estimate the maturity of the child's skeletal system.
Study: NCT05690815

Intervention type: DRUG
Intervention: Descovy
Description: Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
Study: NCT04627831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-Iohexol
Description: Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol
Description: Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
Study: NCT05402306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: Group metacognitive therapy, mainly with attention training technique over two weeks.
Study: NCT04894448

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Any COVID-19 vaccine (1 or more doses)

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Any COVID-19 vaccine (1 or more doses)
Study: NCT06327217

Intervention type: RADIATION
Intervention: Bilateral hip x-ray
Description: Patients will be asked to visit the clinic for a bilateral hip x-ray, in order to evaluate the degree os osteoarthritis.

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients will be asked to complete questionnaires on function, quality of life and pain (the modified Harris Hip Score (mHHS), Hip Outcome Score (HOS), the World Health Organisation Quality of Life Questionnaire (WHOWOL) and Visual Analogue Scale (VAS) for pain). One question will be asked: 'How satisfied are you with the results of the surgery?' on a 10-point scale.
Study: NCT06183450

Intervention type: DIAGNOSTIC_TEST
Intervention: auditory level
Description: * Evaluation of auditory thresholds through audiometric tests.~* Evaluation of speech comprehension in noise through a vocal audiometry test in noise (FraMatrix).~* Evaluation of spatial auditory behavior and spatial precision using a spatial discrimination test (Minimum Audible Angle) and a static sound localization test in virtual reality.

Intervention type: DIAGNOSTIC_TEST
Intervention: cognitive level
Description: * Evaluation of attention and short-term memory functions with verbal and non-verbal tasks: Digit Span Test and Reading Span Test.~* Evaluation of inhibition capacities using the Stroop Test.~* Evaluation of executive functions, visual attention, reasoning, and mental arithmetic using the Raven's Matrix test.

Intervention type: DIAGNOSTIC_TEST
Intervention: quality of life level
Description: - Evaluation of quality of live level via Speech, Spatial and Qualities of Hearing Scale (SSQ-12) and EuroQol-5D questionnaires.
Study: NCT05054894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange (TPE)
Description: Following all necessary screening and consenting protocol, patients will be scheduled for the plasmapheresis procedure.~Plasmapheresis~On the days of the scheduled procedure, patients will undergo up to 1.5 hours of plasmapheresis treatment. Patients will be awake and situated in a relaxed position in a reclined chair. The plasmapheresis device to be used is the Fresenius Kabi 'Amicus', which is currently FDA approved for a variety of clinical conditions. In one treatment, roughly 60-70% of a patient's plasma can safely be replaced; by using six consecutive treatments, more of the patient's plasma (approaching 100%) will be replaced in an exponential fashion.
Study: NCT05678738

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant Berry Supplementation
Description: Participants who opt-in will be instructed to consume 300mL of the bioactive (antioxidant berry) supplement every morning and afternoon during days of participation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute and Chronic Exercise-Heat Stress
Description: All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute and Chronic Exercise-Heat Stress
Description: All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute and Chronic Exercise-Heat Stress
Description: All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (non-juice) Supplementation
Description: Participants who opt-in will be instructed to consume 300mL of the placebo (non-juice) supplement every morning and afternoon during days of participation.
Study: NCT06412887

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality headset
Description: Meta-Quest 2 virtual reality headset was used in this study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Meta-Quest 2 virtual reality headset was used in this study
Study: NCT04989361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soluble Hyaluronic Acid Microneedle
Description: The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-fractional laser
Description: he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
Study: NCT06205121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OATD-01
Description: OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT05383261

Intervention type: OTHER
Intervention: exercise
Description: aerobic and resisted ex
Study: NCT06018467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 Mg Oral Tablet
Description: Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin 1.250 mg (oral)
Description: five 200mg Quercetin Phytosome capsules, from Thorne

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside 1g (oral)
Description: four 250mg Nicotinamide Riboside Capsules, from Elysium Health
Study: NCT05131477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study: NCT04845620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151 Active
Description: ARQ-151 Cream 0.05% - Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-151 Vehicle
Description: ARQ-151 Cream - Vehicle
Study: NCT06257498

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI scan
Description: MRI scan on open scanner and some questionnaires
Study: NCT06049771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collect blood sample
Description: Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
Study: NCT05835752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study: NCT04905537

Intervention type: OTHER
Intervention: No intervention
Description: It's only observational study. No interventions.
Study: NCT05558449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypnosedation
Description: Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: Midazolam intravenous injection 1 mg until RASS -3

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons.
Study: NCT06175429

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical performance testing
Description: Assessment of physical performance using established clinical tests and scoring systems

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sampling and VOC analysis
Description: Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle ultrasound
Description: Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-based biomarker analysis
Description: Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)